BioSpace News Archive

Eargo, Inc., a medical device company on a mission to improve hearing health, reported its financial results for the second quarter ended June 30, 2022.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2022.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided a corporate update and reported financial results for the second quarter of 2022.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, provided a business update and reported financial results for the quarter and six months ended June 30, 2022.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported financial results and provided business highlights for the second quarter and first six months of 2022.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a global collaboration that provides GSK plc (LSE/NYSE: GSK) an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights.

CinCor Pharma, Inc. announced that it has launched an underwritten public offering of 6,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced the grant of inducement equity awards outside of the company’s 2013 Stock Incentive Plan to its newly appointed chief executive officer, Brian Goff.

Johnson & Johnson announced that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company.